Literature DB >> 20921842

Duloxetine: a review of its pharmacology and use in chronic pain management.

Geoff A Bellingham1, Philip W H Peng.   

Abstract

Duloxetine is a serotonin and norepinephrine reuptake inhibitor that possesses antidepressant and pain-relieving properties. Compared with other antidepressants, it has a high affinity for both norepinephrine and serotonin reuptake transporters, which are relatively balanced. Analgesic onset has been observed within the first week of administration in randomized controlled trials and is likely obtained by enhancing the tone of the descending pain inhibition pathways of the central nervous system. Randomized trials have documented significant analgesic effects for managing chronic pain associated with fibromyalgia and diabetic peripheral neuropathic pain. Studies have also suggested that pain associated with major depressive disorder can be reduced with this medication. Modest effects for headache, osteoarthritic pain, and pain secondary to Parkinson disease have also been documented, but data are obtained from single-blinded or open-label trials that require further corroboration with larger randomized studies. Duloxetine has not yet been directly compared with other antidepressants or anticonvulsants for the treatment of pain syndromes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20921842     DOI: 10.1097/AAP.0b013e3181df2645

Source DB:  PubMed          Journal:  Reg Anesth Pain Med        ISSN: 1098-7339            Impact factor:   6.288


  14 in total

Review 1.  The narcotic bowel syndrome: a recent update.

Authors:  Douglas Drossman; Eva Szigethy
Journal:  Am J Gastroenterol Suppl       Date:  2014-09-10

Review 2.  Duloxetine, an antidepressant with analgesic properties - a preliminary analysis.

Authors:  Adela Hilda Onuţu
Journal:  Rom J Anaesth Intensive Care       Date:  2015-10

Review 3.  Narcotic bowel syndrome and opioid-induced constipation.

Authors:  Eva Szigethy; Marc Schwartz; Douglas Drossman
Journal:  Curr Gastroenterol Rep       Date:  2014-10

4.  Assessment of the Management of Patients with Chronic Pain Referred to a Specialized Pain Unit: A Cross-Sectional Multicenter Study (the DUO Project).

Authors:  Víctor Mayoral Rojals; Ángeles Canós Verdecho; Begoña Soler López
Journal:  J Clin Med       Date:  2022-06-22       Impact factor: 4.964

Review 5.  Antidepressants for hip and knee osteoarthritis.

Authors:  Alexandra A Leaney; Jenna R Lyttle; Julian Segan; Donna M Urquhart; Flavia M Cicuttini; Louisa Chou; Anita E Wluka
Journal:  Cochrane Database Syst Rev       Date:  2022-10-21

6.  Abnormal connectivity model of raphe nuclei with sensory-associated cortex in Parkinson's disease with chronic pain.

Authors:  Yalian Shen; Juan Wang; Juan Peng; Xiaolin Wu; Xiaocui Chen; Jinjin Liu; Min Wei; Dezhi Zou; Yu Han; Anran Wang; Oumei Cheng
Journal:  Neurol Sci       Date:  2022-01-08       Impact factor: 3.830

Review 7.  Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.

Authors:  Kate E Roberts; India T Adsett; Kirsty Rickett; Sophie M Conroy; Mark D Chatfield; Natasha E Woodward
Journal:  Cochrane Database Syst Rev       Date:  2022-01-10

8.  Efficacy of Duloxetine in Patients with Chronic Pain Conditions.

Authors:  Vladimir Skljarevski; Shuyu Zhang; Smriti Iyengar; Deborah D'Souza; Karla Alaka; Amy Chappell; Joachim Wernicke
Journal:  Curr Drug ther       Date:  2011-11

9.  Myoclonus in renal failure: Two cases of gabapentin toxicity.

Authors:  Kenneth R Kaufman; Amay Parikh; Lili Chan; Mary Bridgeman; Milisha Shah
Journal:  Epilepsy Behav Case Rep       Date:  2013-12-29

10.  Predictors of duloxetine adherence and persistence in patients with fibromyalgia.

Authors:  Zhanglin Cui; Yang Zhao; Diego Novick; Douglas Faries
Journal:  J Pain Res       Date:  2012-06-22       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.